EGFR and lung adenocarcinoma: The two most common EGFR-activating mutations in NSCLC are in-frame deletions in exon 19 and the L858R point mutation in exon 21, accounting for 45% and 40–45% of lung adenocarcinoma patients, respectively [4,7].